B

Boston Scientific

Medical devices maker for interventional specialties

R&D Leads Sustaining Engineer Intern

Summer 2027Updated
$43.4k - $73.7k+ Overtime + Shift differential + Annual bonus target
Internship
Bachelor's, Master's
Arden Hills, MN, USA
In PersonOnsite at the local office at least five days per week; reliable transportation to and from Arden Hills is required.
Biology & BiotechBiomedical Engineering & Medical Devices
No H1B Sponsorship

About the job

Requirements
  • The candidate must be a current rising senior with a graduation date between December 2027 and May 2029.
  • The candidate must be working toward a Bachelor's or Master's degree in Mechanical or Biomedical Engineering.
  • The candidate must be able to start the internship on May 17 or May 24, 2027, and work for 12 weeks.
  • The candidate must have hands-on prototyping and testing experience through academic projects or professional roles.
  • The candidate must be familiar with CAD software such as SolidWorks for component or system design.
  • The candidate must have basic data and statistical analysis experience, such as using t-tests to compare group data.
  • The candidate must be eligible to work in the United States without company sponsorship, now or in the future, for employment-based work authorization.
  • The candidate must have reliable transportation to and from the Boston Scientific location in Arden Hills, Minnesota.
  • The role is safety-sensitive, and candidates are subject to a prohibited substance test.
Responsibilities
  • Support the design and development of implantable cardiac devices within the Active Implantable Systems group.
  • Contribute to hands-on prototyping and testing of device components and supporting technologies.
  • Create and refine computer-aided design models for implantable systems and related tooling.
  • Analyze performance data from bench testing, simulations, or clinical feedback to inform design decisions.
  • Apply basic and advanced statistical methods to evaluate design robustness and process performance.
  • Collaborate with cross-functional teams to ensure device safety, reliability, and clinical efficacy across the continuum of care.
  • Participate in documentation, design reviews, and validation activities to meet regulatory and quality standards.
  • Engage in problem-solving and iterative development to address unmet clinical needs and improve patient outcomes.
  • Contribute to innovation efforts that challenge existing paradigms and expand what is possible in cardiac care.
Desired Qualifications
  • Medical industry experience.
  • Advanced statistical techniques, such as process performance analysis or design of experiments.
  • Ability to communicate effectively with diverse, cross-functional teams.
  • Interest in learning new technologies and finding new solutions.

About the company

B

Boston Scientific

View
Website

Boston Scientific designs and makes medical devices used in procedures across cardiology, endoscopy, urology, and neuromodulation. Its products help doctors diagnose and treat conditions by guiding minimally invasive interventions and delivering therapies inside the body, with revenue from hospitals and clinics. The firm differentiates itself through a broad, global portfolio and heavy ongoing investment in research and development to expand capabilities and address complex health issues. Its goal is to improve patient care by providing reliable, effective medical devices and solutions that enable clinicians to perform safer, more effective procedures while growing its business.

Company Size

10,001+

Company Stage

IPO

Headquarters

Marlborough, Massachusetts

Founded

1979

Get referred to Boston Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 11, 2026 FDA clearance for SpaceOAR Flex expands prostate cancer workflow offerings.
  • Boston Scientific restored remote cardiac monitoring and most operations by September 8, 2026.
  • Second-quarter 2026 sales grew 7.5%, showing strong demand before the cyber disruption.

What critics are saying

  • August 25, 2026 cyberattack forced Boston Scientific to miss 2026 sales and profit guidance.
  • September 25, 2026 FDA Class I recall removed Imager II Angiographic Catheters after tip defects.
  • AXIOS and Infinion CX recalls show repeated manufacturing and design-quality failures across franchises.

What makes Boston Scientific unique

  • FARAPULSE remains Boston Scientific's category-defining pulsed-field ablation franchise in 2026.
  • SpaceOAR Flex extends a differentiated prostate-radiotherapy portfolio with real-time flexible delivery.
  • Global scale across cardiology, endoscopy, urology, and neuromodulation diversifies procedure-dependent revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Relocation Assistance
  • Performance Bonus

Growth & Insights and Company News

6 month growth

5%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 28th, 2026
Boston Scientific hit by cyber outage and cyclical slump, plans $500M savings as 2027 seen as trough

Boston Scientific said a cyber security incident hurt its third-quarter results, causing a two-week outage with eight business days of manufacturing and shipping disruption. The attack cut sales growth by about 300 basis points and earnings per share by $0.07, and lost revenue came to $150 million. The company expects 2027 to be the low point of its cycle, with recovery in 2028. Weakness in its electrophysiology and WATCHMAN franchises, and pricing pressure in China, weigh on growth. A restructuring programme should save more than $500 million over three years. It also booked an $80 million charge, mostly for product liability cases. The Penumbra acquisition is now expected to close in early 2027 because of regulatory timelines.

Yahoo Finance
Oct 28th, 2026
Boston Scientific beats Q3 revenue with $5.14B but Q4 guidance of $5.18B misses; shares fall 3%

Boston Scientific beat third-quarter revenue estimates but gave weak guidance for the next quarter. Revenue rose 1.4% year on year to $5.14 billion, against analyst expectations of $5.07 billion. Adjusted earnings per share were $0.73, in line with estimates. The medical device maker guided fourth-quarter revenue to $5.18 billion at the midpoint, below the $5.42 billion analysts expected. It also cut its full-year adjusted earnings per share guidance to $3.17 at the midpoint, a 3.9% decrease. Operating margin fell to 16.1% from 20.7% a year earlier. Shares fell 3% to $43.71 after the results. Chief executive officer Mike Mahoney called it "a challenging year," citing the cybersecurity incident, but said he remains confident in the company's long-term strategy.

PR Newswire
Oct 28th, 2026
Boston Scientific Q3 sales rise 1.5% to $5.14B as cyberattack weighs; Q4 decline forecast

Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% from a year earlier. The company said the period was hit by a cybersecurity incident first reported on August 26, 2026. GAAP net income fell to $582 million, or $0.40 per share, from $755 million, or $0.51 per share. Adjusted earnings per share were $0.73, compared with $0.75 a year ago. Cardiovascular sales rose 1.9%, while MedSurg grew 0.6%. By region, Latin America and Canada grew 16.0%, and the US rose 0.5%. The company now expects full-year net sales growth of about 4.25% and adjusted earnings per share of $3.16 to $3.18. It expects fourth-quarter sales to fall 1% to 3%.

Nine80 Digital
Oct 20th, 2026
Boston Scientific Recalls 199 Microcatheters Distributed to South African Hospitals.

Boston Scientific Recalls 199 Microcatheters Distributed to South African Hospitals. Thomas October 20, 2026 Boston Scientific Recalls 199 Microcatheters Distributed to South African Hospitals. Boston Scientific has recalled 199 Direxion and Direxion HI-FLO Torqueable Microcatheters distributed to healthcare facilities across South Africa, following a manufacturing issue that could affect the devices' movement during medical procedures. The recall, dated 20 October 2026, affects products supplied to healthcare facilities including Diagnostic Radiological Services, Groote Schuur Hospital, Netcare facilities, Life Wilgers Hospital, Life Peglerae Hospital, Capital Radiology and other healthcare providers. According to the supplier, the manufacturing issue may make it difficult to remove the affected microcatheter from its carrier hoop or to advance and withdraw it through a guide catheter. Increased resistance during these processes may damage the device, potentially affecting its performance during a procedure. The recalled products are single-lumen, multipurpose microcatheters used by healthcare professionals to access treatment sites in the peripheral vasculature during medical procedures. The supplier has identified life-threatening embolism as the most serious potential harm associated with a dysfunctional microcatheter. The likelihood of this occurring has been assessed as remote. The National Consumer Commission (NCC) has advised healthcare professionals to immediately discontinue use of the affected products. Healthcare facilities have also been advised to remove the affected devices from their inventories and segregate them in a secure location while awaiting their return to Boston Scientific. The NCC further advised healthcare professionals to consult the supplier's recall notice to verify whether products in their possession are affected by checking the relevant product and lot numbers. The recall applies to the identified Direxion and Direxion HI-FLO Torqueable Microcatheters distributed to healthcare facilities nationally. The NCC's guidance is directed at healthcare professionals and facilities handling the affected devices, with the immediate focus on preventing further use of products covered by the recall. Boston Scientific is the biomedical and biotechnology company supplying the recalled devices. The recall follows the identification of the manufacturing issue affecting removal from the carrier hoop and advancement or withdrawal through a guide catheter.

Yahoo Finance
Oct 15th, 2026
Boston Scientific risk rises as $2.72B capex tops R&D for the first time since 2011

Boston Scientific shares have fallen 54.7% over the past year, against a 17.3% gain for the S&P 500, even as the medical device maker grew revenue 13.5% in the twelve months to June 2026. In August, a cyberattack disrupted its manufacturing and order shipments. Risk has risen because capital spending reached $2.72 billion, above the $2.15 billion spent on research. Research had led at every quarter end since at least September 2011. Most of the extra spending came in April to June, at $1.93 billion versus $245 million a year earlier. Free cash flow fell to $1.81 billion from $3.18 billion, while total debt rose to $12.6 billion from $12.0 billion. On July 29, management cut its 2026 revenue growth forecast to 6.0% from 7.8%. The next report, expected around October 28, 2026, covers the quarter the attack hit.